Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

15.40USD
24 Feb 2017
Change (% chg)

$0.30 (+1.99%)
Prev Close
$15.10
Open
$15.05
Day's High
$15.50
Day's Low
$14.95
Volume
256,639
Avg. Vol
185,667
52-wk High
$19.90
52-wk Low
$7.86

MNTA.OQ

Chart for MNTA.OQ

About

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox... (more)

Overall

Beta: 1.75
Market Cap(Mil.): $1,076.82
Shares Outstanding(Mil.): 71.31
Dividend: --
Yield (%): --

Financials

  MNTA.OQ Industry Sector
P/E (TTM): -- 44.59 29.71
EPS (TTM): -0.31 -- --
ROI: -5.32 -3.18 12.94
ROE: -5.66 5.86 14.09

BRIEF-Momenta Pharmaceuticals Q4 earnings per share $0.60

* Momenta Pharmaceuticals reports fourth quarter and year end 2016 financial results

Feb 21 2017

BRIEF-Momenta Pharmaceuticals announces FDA warning letter to contracted Glatopa

* Momenta Pharmaceuticals announces FDA warning letter to contracted glatopa (glatiramer acetate injection) fill/finish manufacturer

Feb 17 2017

BRIEF-Momenta Pharmaceuticals announces HSR clearance

* Momenta Pharmaceuticals announces Hart-Scott-Rodino clearance for collaboration and license agreement with CSL

Feb 17 2017

BRIEF-Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation

* Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation Source text for Eikon: Further company coverage:

Jan 31 2017

BRIEF-Momenta provides year-end 2016 corporate update

* Momenta Pharmaceuticals Inc - reiterated its non-gaap operating expense guidance of approximately $40 - $45 million for Q4 of 2016

Jan 06 2017

Momenta's Humira biosimilar succeeds in key psoriasis study

U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

UPDATE 1-Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

BRIEF-Momenta Pharmaceuticals says positive top-line phase 3 results for M923, a proposed Humira biosimilar

* Momenta Pharmaceuticals announces positive top-line phase 3 results for M923, a proposed Humira (adalimumab) biosimilar

Nov 29 2016

Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 U.S. biotech company Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

BRIEF-Momenta Pharmaceuticals names Scott Storer as CFO

* Says Storer is expected to begin at Momenta on november 28, 2016 and will replace Momenta's current CFO Rick Shea

Nov 02 2016

More From Around the Web

Competitors

Earnings vs. Estimates